FDA Approves Landmark Cancer Therapy; Wilmot Positioned Among First to Offer It

UR Medicine ’s Wilmot Cancer Institute will be among the first sites in the world to offer CAR T-cell therapy —a new type of immunotherapy—to adults with aggressive lymphoma. The engineered gene therapy has been described as a revolutionary “living drug” and one of the most powerful cancer treatments to emerge in recent years.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Authors: Source Type: news

Related Links:

Primary pulmonary lymphoma is a relatively uncommon disease in both the thoracic and lymphoproliferative spectrum of cancers, accounting for only up to 1% of primary pulmonary malignancies and fewer than 1% of all lymphomas.1 Diagnosis requires pathologic confirmation of the lymphoproliferative disorder in the lungs, with no detectable extrathoracic manifestations of the disease for at least 3 months after the initial diagnosis to avoid accidental inclusion of lymphoma that has secondarily progressed to involve the lungs.
Source: Contemporary Diagnostic Radiology - Category: Radiology Tags: Article Source Type: research
The proto-oncogene β-catenin drives colorectal cancer (CRC) tumorigenesis. Casitas B-lineage lymphoma (c-Cbl) inhibits CRC tumor growth through targeting nuclear β-catenin by a poorly understood mechanism. In addition, the role of c-Cbl in human CRC remains largely underexplored. Using a novel quantitative histopath ologic technique, we demonstrate that patients with high c-Cbl–expressing tumors had significantly better median survival (3.7 years) compared with low c-Cbl–expressing tumors (1.8 years; P = 0.0026) and were more than twice as likely to be alive at 3 years compared with low c-Cb...
Source: American Journal of Pathology - Category: Pathology Authors: Tags: Regular article Source Type: research
CONCLUSIONS: Absolute numbers of cases of HL at our centre have increased since the roll-out of antiretroviral therapy (ART) to the public sector. The recent change in policy to make ART available to all HIV-positive patients independent of CD4+ count suggests that patients will survive longer and are therefore at increased risk of developing HL. We anticipate that numbers of HL cases will increase or remain high in the coming years, and we need to prepare for this. PMID: 30004343 [PubMed - in process]
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
Conclusions: Taken together, this work demonstrated that miR-181b might have the ability to overcome chemo resistance of small cell lung cancer cells, and restoration of this miRNA may represent a potential therapeutic strategy for improving chemo sensitivity in small cell lung cancer. PMID: 30002690 [PubMed]
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research
I read with interest the proposal of the European Organisation for Research and Treatment of Cancer (EORTC) cutaneous lymphoma task force concerning B ratings based on absolute counts of CD4+CD26 − or CD4+CD7− lymphocytes, that is, B0,
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
The comments on blood class in erythrodermic cutaneous T-cell lymphoma (CTCL) from E. Vonderheid are received with interest by our European Organisation for Research and Treatment of Cancer (EORTC) group. First, it should be noted that our recent EORTC consensus statement defined blood class according to flow cytometry [1] and included all patients with mycosis fungoides (MF) and Sezary syndrome (SS). E. Vonderheid commented on blood class in erythrodermic MF/SS, and it must be recognised that blood involvement is much more frequent in erythrodermic CTCL than patch, plaque and tumour stage MF p  
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
ConclusionsOur findings are not consistent with a discernable effect of cellphone use patterns in Israel on incidence trends of brain, CNS and intracranial tumors.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Conclusions: TP53 mutations reduce responsiveness to crizotinib and worsen prognosis in ALK rearrangement NSCLC patients. PMID: 29997966 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Condition:   Lymphoma Intervention:   Drug: Pembrolizumab Sponsor:   Abramson Cancer Center of the University of Pennsylvania Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions.   It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell lung cancer, and multiple myeloma.  In neuroblastoma, patients undergo a very aggress ive standard of care regimen that results in a high mortality rate.  Many neuroblastomas have increased expression of CD56, which represents a possible therapeutic target for these...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Gene Therapy | Genetics | Lymphoma | Universities & Medical Training